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Abstract 
 Cell based therapies for bone regeneration are an exciting emerging technology, but the 
availability of osteogenic cells is limited and an ideal cell source has not been identified.  
Amniotic fluid-derived stem (AFS) cells and bone-marrow derived mesenchymal stem cells 
(MSCs) were compared to determine their osteogenic differentiation capacity in both 2D and 3D 
environments.  In 2D culture, the AFS cells produced more mineralized matrix but delayed peaks 
in osteogenic markers.  Cells were also cultured on 3D scaffolds constructed of poly-ε-
caprolactone for 15 weeks.  MSCs differentiated more quickly than AFS cells on 3D scaffolds, 
but mineralized matrix production slowed considerably after 5 weeks.  In contrast, the rate of 
AFS cell mineralization continued to increase out to 15 weeks, at which time AFS constructs 
contained 5-fold more mineralized matrix than MSC constructs.  Therefore, cell source should be 
taken into consideration when used for cell therapy, as the MSCs would be a good choice for 
immediate matrix production, but the AFS cells would continue robust mineralization for an 
extended period of time.  This study demonstrates that stem cell source can dramatically 
influence the magnitude and rate of osteogenic differentiation in vitro. 
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1. Introduction 
Little is known about the optimal cell source for tissue engineering of cell-based 
therapies for musculoskeletal tissues.  Bone graft substitutes composed of a biodegradable 
scaffold containing stem cells capable of osteogenic differentiation have shown promise as an 
alternative to bone grafting or delivery of osteoinductive proteins.  This cellular augmentation is 
especially important in clinical cases where endogenous cellular supply is diminished, such as in 
older patients, smokers, or after chemotherapy or radiation therapy.   
  Mesenchymal stem cells (MSCs) are believed to be the source of osteoblastic cells 
during normal bone growth and remodeling and may be isolated from the bone marrow, among 
other tissues.  Mesenchymal stem cells are a sub-population of bone marrow-derived cells 
characterized by their ability to differentiate to the mesenchymal lineage tissues of bone, fat and 
cartilage, as well as muscle[1-7].  Additionally, MSCs can be isolated from the intended 
recipient, thus reducing the probability of rejection[8].  Their relative ease of isolation and 
differentiation capability makes MSCs potentially useful for many applications, including bone 
deficits[9].  Osteogenic differentiation of MSCs has been well characterized.  With the addition 
of just a few supplements to the basal growth media, often referred to as osteoinductive factors 
including dexamethasone, B-glycerophosphate and ascorbic acid, MSCs will mineralize the 
surface of a two-dimensional surface[2, 10, 11].  Furthermore, MSCs have been used in 3D 
constructs to mineralize bone graft substitutes[12-14].     
 Human amniotic fluid-derived stem (AFS) cells are isolated from amniotic fluid after 
routine amniocentesis[15-22].  The AFS cells express both embryonic and adult stem cell 
markers and are broadly multipotent; they can be induced to differentiate into cells representing 
all three embryonic lineages, such as cells of the osteogenic, adipogenic, chondrogenic, 
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myogenic, endothelial, neuronal, and hepatic lineages[17, 23-29].  Unlike embryonic stem cells, 
AFS cells are not tumorigenic and can expand extensively without the use of feeder layers or 
expensive defined media[23].  The AFS cell lines have been shown to expand over 250 
population doublings and retain telomere length and have a normal chromosomal karyotype[23].   
Therefore, AFS cells have great potential for cellular tissue engineering.  Previously, AFS cells 
have been shown to be capable of producing robust mineralized matrix in two-dimensional 
culture and throughout a three-dimensional medical grade poly-ε-caprolactone (PCL) scaffold 
and nanofiberous scaffolds[24, 30-32].  This study compares the ability of the adult and fetal 
stem cell sources to produce mineralized matrix in 2D and 3D culture.   
Tissue engineering strategies using an extracellular matrix combined with stem cells 
capable of osteogenic differentiation may therefore be used to develop bone graft substitutes. 
The aim of this study was to compare two cell sources for potential application in the tissue 
engineering of bone graft substitutes. Comparison of human fetal-derived AFS cells and MSCs 
for the production of bone graft substitutes will help elucidate the most appropriate cell source 
for particular applications and may suggest appropriate delivery strategies.  By culturing cells on 
3D scaffolds, it was determined that the AFS cells had greater osteogenic potential overall, but 
they were observed to take longer to differentiate than the MSCs.   
 
2  Results 
 
2.1 2D differentiation:   
The morphology of the AFS cells was heterogeneous, but overall there appeared to be 
two general morphologies with one very small and compact and the other more spindle shaped 
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(Supplemental Figure 1 A and B).  The MSCs were also heterogeneous, but to a lesser extent 
than the AFS cells.  The MSCs were spindle shaped and visibly larger than the AFS cells 
(Supplemental Figure 1C).  The AFS cells and MSCs both differentiated into mineral producing 
cells when grown on tissue culture plastic.  The mineralized matrix was visualized by the alizarin 
red S staining of calcium that covers the cells (Supplemental Figure 1 D-F).   
 
2.2 Biochemical assay of 2D mineralized matrix:   
Although the staining appeared to be qualitatively similar between the cell types 
(Supplemental Figure 1 D-F), when the alizarin red was extracted and quantified, the AFS cells 
demonstrated significantly more mineral deposition/staining at 2 and 4 weeks (Figure 1A).  The 
increased mineralized matrix was confirmed by calcium extraction and quantification by 
Arsenazo III reagent (Figure 1B).  The AFS cell mineralized matrix contained significantly more 
Calcium than the matrix produced by the MSCs.  
 
2.3 Gene Expression:   
The expression levels of mRNA for Runx2, Alkaline Phosphatase and Osteocalcin were 
examined during osteogenic differentiation of the AFS cells and MSCs.  Runx2 is a transcription 
factor  involved in regulating osteogenic and chondrogenic differentiation and maintenance.    
Alkaline Phosphatase (ALP) is a phosphatase associated with mineralized matrix production.  
Osteocalcin is a vitamin D and K dependent protein produced by osteoblasts and is a common 
marker of bone formation.    
In all three genes analyzed, the MSCs had a peak in gene expression between days 3 and 
5 of differentiation (Figure 1, C-E).  The AFS cells did not show this initial peak in gene 
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expression but rather gradually increased expression over the 14 day culture.  The ALP gene 
expression is consistent with previously reported findings that the MSCs have a higher ALP level 
at 1 week, at 2 weeks the levels are similar, and at 3 weeks the AFS cells have a higher ALP 
level[33].  The temporal differences in the gene expression support the hypothesis that the AFS 
cells are in a more primitive state and require additional time to differentiate into osteoblasts.     
 
2.4 Osteogenic Differentiation in 3D PCL scaffolds:   
The AFS cells and MSCs were seeded onto PCL scaffolds with lyophilized collagen.  
The lyophilized collagen filled the scaffold pores to enhance cell retention and the composite 
scaffolds were placed in non-cell binding plates to encourage cell attachment.  The seeding 
efficiencies of the cell types were not significantly different (Figure 4C).  Both the AFS cells and 
MSCs had visually occluded the pores by 5 weeks.   
 The mineralized matrix production by the cells was quantified by microCT analysis.  The 
3D renderings of the mineralized matrix are shown in Figure 2.  The AFS cells had sparse 
mineral deposition at 3 and 5 weeks.  By 10 weeks the AFS cells had produced substantial 
mineral throughout the PCL scaffold.  Conversely, the MSCs showed more mineral production at 
the early time points, and the mineral content was not enhanced by the additional culture time.  
Additionally, the spatial distribution of the mineralized matrix appeared to be cell-source 
specific. The AFS cells routinely produced mineral throughout the entire scaffold, whereas the 
MSCs only produced mineral in the center of the scaffold, even though there were cells found 
throughout the scaffold (Figure 2 and Figure 5 E, I, and M).The mineralized matrix production 
by the AFS cells on 3D constructs is highly reproducible, as is illustrated by four representative 
microCT images of each cell line at 15 weeks, see Supplementary Data Figure 3. 
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2.5 Quantification of 3D Mineralized Matrix:   
The quantity of mineralized matrix was determined by the microCT scan, and the 
averages are shown in Figure 3A.  The MSCs produced significantly more mineral at the 3 and 5 
week time points, but their mineralization capacity was limited to the first few weeks in culture.  
Alternatively, the AFS cells did not produce substantial mineralized matrix until 5 weeks in 
culture, with mineralized matrix production increasing throughout the 15 weeks in culture.  At 3 
and 5 weeks, the MSCs had produced significantly more mineralized matrix than the AFS cells 
(p<0.001), but by 15 weeks the AFS cells had produced 3 times more mineralized matrix than 
the MSCs (p< 0.001).  At all time points, cells grown in osteogenic media produced more 
mineralized matrix than those grown in control media (p<0.001).   
Two AFS cell lines were available at the time of this study and their differentiation 
potential was compared.  Little variability was seen in the osteogenic differentiation of the A1 
and H1 AFS cell lines. The mineralized matrix volume did not differ until 15 weeks in culture at 
which time the H1 AFS cells had produced more mineralized matrix than the A1 AFS cells.  
Both AFS cell lines produced approximately 5 times the mineralized matrix than the MSCs at 15 
weeks.  The AFS cell control media constructs also had more mineralized matrix than the MSC 
control constructs at 15 weeks (p<0.05), which may indicate greater spontaneous differentiation 
of the AFS cells in the absence of osteogenic cues.  
 
2.6 Rate of 3D Mineralization:   
The scaffolds were scanned sterile and returned to culture.  Therefore, the rate of 
mineralized matrix production was determined by quantifying the new mineral volume since the 
previous scan and dividing by the number of weeks between scans.  The average rate of 
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mineralized matrix production (Figure 3B) by the MSCs was greater at 3 weeks than the AFS 
cells (p<0.001).  By 5 weeks, the rate of mineralization of the cell types was not significantly 
different.  At 10 and 15 weeks, the AFS cells were producing mineralized matrix at a greater rate 
than the MSCs (p<0.001).  Additionally, at 10 and 15 weeks the MSCs were producing 
mineralized matrix with a rate that is indistinguishable from the control cells.   
 
2.7 Calcium Content and Cell Number:  
The AFS cells produced significantly more mineralized matrix, as analyzed by calcium 
concentration, than the MSCs (Figure 4A).  Additionally, both the MSCs and AFS cells 
produced significantly more mineralized matrix when placed in osteogenic media than in control 
media (n=6, p<0.001).  This increased mineralization was not due to an increased cell number, 
but to an increased matrix deposition as the AFS cells and MSCs attached to the scaffold in 
comparable numbers (Figure 4C).  The seeding efficiency was comparable for both cell types on 
the PCL scaffold.  After 15 weeks in culture, both the AFS cell and MSC seeded scaffolds had 
similar cell number whether cultured in control or osteogenic media, as determined by DNA 
content (Figure 4D).   Therefore, human AFS cells demonstrated an increased long-term 
osteogenic differentiation and mineralized matrix production capacity compared to human 
MSCs.   
 
2.8 Cell Viability:  
After 15 weeks in culture, cell viability was determined by a live-dead assay that relied 
on the intracellular esterase activity and plasma membrane integrity, two measures of cell 
viability, to discriminate between live and dead cells.  Photomicrographs of the exterior surfaces 
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(top, bottom and exterior circumference) are shown (Figure 4B).  Additionally, the cells at the 
interior of the scaffolds were examined by cutting the scaffold longitudinally. It can be observed 
that even after 15 weeks in culture, the cell viability is very high in all the scaffolds.   
 
2.9 Histology:  
Histological examination of the scaffolds after 15 weeks, using resin embedding and 
microtome sectioning to 5µm followed by von Kossa staining revealed no mineralisation for the 
control (MSCs in CCM) PCL scaffolds (Figure 5 A-D). Only pink stained fibrous tissue can be 
observed. Whereas the onset of bone formation was observed for osteoinduced MSC and AFS 
cells which were seeded into 3D PCL scaffolds. Mineral nodules containing calcium, stain black 
with the von Kossa staining by virtue of silver ions (positive charge) binding with the 
mineralised tissue (negative portion of the calcium salt) forming a silver salt which is black in 
colour. Clear black mineral deposition can be observed for osteinduced MSCs (Figure 5 E-H) 
and AFS cells (I-P), within a fibrous network penetrating the scaffold pores. Residual PCL 
scaffold was evident within all transplants as evidenced by voids in the tissue from longitudinal 
and transverse sectioning of the scaffold struts. It can be noted that the pattern of mineral 
deposition was different between each cell type and seems to favour a more central scaffold 
locality for MSC cells whereas the AFS cells seem to deposit throughout the entire scaffold both 
centrally and at the periphery. 
 
3  Discussion 
This study demonstrates the mineralization potential of a fetal and adult stem cell 
population.  The fetal AFS cells demonstrated an increased duration of mineralized matrix 
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production, but the MSCs were capable of robust differentiation at the earlier time points.  After 
15 weeks in 3D culture, the AFS cells had produced approximately 20 mm
3
 of mineralized 
matrix, whereas the MSCs had produced approximately 4 mm
3
 by 5 weeks, which did not 
increase thereafter. MicroCT analysis showed the mineralization for MSC scaffolds constructs 
was located mainly within the central core of the scaffold as opposed to the AFS cells which 
mineralized the entire scaffold including the outer edges.  
In 2D culture, the AFS cells differentiate readily and using a standard time course it is not 
evident that there is a lag in differentiation by these cells.  Quantitative PCR comparing 
osteogenic gene expression between the two cell sources in 2D revealed a lag in the AFS cells 
when compared to the MSCs.  This supports the longer induction time necessary for the AFS 
cells to differentiate to osteoblasts.  The sensitivity of the staining of the extracellular matrix in 
2D culture was not capable of determining these early differences in the cell differentiation 
because by 14 days the gene expression by the AFS cells matched or exceeded the expression in 
the MSCs.   
The 15 week in vitro culture protocol used in this study provided a very challenging 
culture system to examine long term potential of the cell sources.  When grown in a large 6mm x 
9mm PCL scaffold, the AFS cells had great potential but the cells required an extensive 
induction time prior to their osteogenic differentiation.  Current studies often culture cells within 
3D scaffolds for less than 6 weeks but this time period would not have shown the potential of the 
AFS cells.  Early time points suggest the MSCs have a greater potential, but the AFS cells have a 
greater overall mineralized matrix production capacity when examined after an extensive culture 
period.  This supports the hypothesis that the AFS cells have a longer induction period than the 
MSCs, which may be due to their fetal origins.   
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The mineral deposition distribution found by microCT was supported by histological 
examination which demonstrated that the pattern of black stained mineral deposition was 
different between each cell type and seems to favour a more central scaffold locality for MSC 
cells whereas the AFS cells seem to deposit throughout the entire scaffold both centrally and at 
the periphery. This could be due to the MSCs requiring local mineral presence in order to 
nucleate more mineral production which leads to a tendency to concentrate their cells actively 
capable of mineralisation within the same area (in the scaffold core in this case) whereas AFS 
cells might be more capable of spontaneous mineralisation without the requiring any prerequisite 
mineral existing in close proximity. Alternatively the mineral nucleation sites (such as those 
present on collagen or denatured collagen) [34] might have been distributed more centrally in the 
case of the MSC scaffold constructs compared to the AFS scaffold constructs. It certainly 
highlights the differences in mineralisation capacities of these different cells from a temporal, 
spatial and rate perspective. 
Serial microCT scans of scaffolds were performed which allowed the determination of 
the change in matrix within each scaffold over the 15 weeks in culture.  The rate of mineralized 
matrix production was higher for the MSCs at the beginning of the culture but the cells did not 
produce detectible mineralized matrix after the 5 week scan.  The AFS cells had a low rate of 
mineralization for the first 3 weeks, but the rate increased thereafter and continued to increase 
over the 15 weeks of culture.  This may be due to the more primitive state of the fetal AFS cells 
needing additional time or cell density before they will differentiate to osteoblasts.   
Although the rate of MSC mineralized matrix production decreased after 5 weeks, the 
cells maintained high viability throughout the culture.  At 15 weeks, the cells were found 
throughout the scaffolds and there was minimal cell death in scaffolds seeded with either cell 
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type without bias for the spatial localization within the scaffold.  Additionally, the AFS cells and 
MSCs had similar cell numbers attach to the scaffold after 15 weeks in culture so the difference 
in matrix production was not due to cell proliferation or apoptosis.  Maintaining the high 
viability achieved in vitro will be imperative to have similar results in vivo.  The long induction 
time for the AFS cells may make this even more challenging.  Co-implantation of both MSCs 
and AFS cells may prove beneficial as the MSCs could provide immediate mineralized matrix 
production and the AFS cells will provide long-term support.   
 Cell-based tissue engineering strategies represent a clinical alternative to bone grafting 
and the delivery of osteoinductive proteins[35]. However, cell sourcing is a critical issue for cell-
based therapies which aim to regenerate musculoskeletal tissues, and this issue needs to be 
addressed[9, 36]. Tissue engineering approaches that combine biodegradable scaffolds with stem 
cells capable of osteogenesis have shown promise as an effective bone graft substitute[37]. Cell-
based engineered bone grafts are an attractive alternative to allografts or autografts, particularly 
when the endogenous supply of stem cells is depleted through advanced age or concurrent 
therapy[12, 38, 39].  Several factors are critical for the choice of transplanted cells, such as: a) 
availability in sufficient numbers for therapeutic use, b) immune-tolerance, and c) the ability to 
promote bone formation on a therapeutic timescale.    
Despite well known developmental differences in tissue regeneration and scar formation, 
very little is known about the differences in phenotype and regenerative capacity of stem cells 
isolated from different human developmental stages. Although there is evidence that allogeneic 
stem cells promote bone repair, many tissue-engineering studies have been limited by a lack of 
quantitative outcome measures to allow direct comparisons between different stem cell sources.  
Purified mesenchymal stem cells (MSCs) derived from bone marrow have been shown to 
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enhance repair of critically-sized defects in preclinical animal studies[38, 40]. 
 Many questions still remain pertaining to the use of stem cells for regenerative medicine.  
Although we have shown that the AFS cells have an increased osteogenic capacity than the 
MSCs in vitro, the comparison of this capacity in vivo is of greater clinical significance.  Critical 
factors are still unknown for the optimal delivery strategy, such as:  a) should the cells be 
undifferentiated or pre-differentiated in culture prior to implantation, b) are exogenous factors 
such as pro-angiogenic growth factors important for revascularization, c) what is the optimal 
time point for implantation post-trauma, d) how many cells should be delivered and should they 
be implanted in one site as a bolus or at multiple implantation sites or specific designated times?  
There is vast potential for stem cells in regenerative medicine, and determining the optimal cell 
source will certainly improve patient outcome.   
 
4. Methods 
 
4.1 Amniotic fluid stem cell culture:   
Human AFS cells were kindly provided by the Institute for Regenerative Medicine at 
Wake Forest University[23].  In this study, two cell lines were available and both were analyzed, 
A1 and H1 human AFS cells.  The AFS cells were received at passage 14, and further expanded 
2-3 times in α-MEM medium containing 15% FBS, 2mM L-glutamine, 100 units penicillin, 100 
µg streptomycin (all Invitrogen, Carlsbad, Ca), supplemented with 18% Chang B and 2% Chang 
C (Irvine Scientific, Santa Ana, CA) at 37˚C with 5% CO2 atmosphere.  This media is referred to 
in this paper as modified Chang media.  AFS cells were sub-cultured at a dilution of 1:10 and not 
permitted to expand beyond 70% confluence in the modified Chang media on Integrid plates 
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(BD Falcon, San Jose, CA).  Cells were frozen in the modified Chang media supplemented with 
5% DMSO.  For experimental use, 1x10
6
 AFS cells were quickly thawed to 37˚C and placed in 
10, 150-mm Integrid culture plates with modified Chang media.  After 5 days, the cells were 
harvested with 0.25% trypsin-EDTA (Invitrogen), counted and used experimentally. 
 
4.2 Mesenchymal stem cell culture:   
Human MSCs were generously provided by the Tulane Center for Gene Therapy through 
the NIH-funded center for preparation and distribution of adult stem cells (2P40RR017447-06).   
MSCs from four adult donors were expanded by plating the cells at an initial density of 50 cells 
per cm
2
 and cultured in complete culture media (CCM) or also referred to as Control Media.  
CCM consists of alpha-modified minimal essential media (αMEM, Invitrogen) supplemented 
with 17% FBS (Atlanta Biologicals), 2mM L-glutamine, 100 units penicillin, 100 µg 
streptomycin (all Invitrogen).  Cells were cultured on tissue culture dishes (Nuncleon Δ surface, 
Thermo Fisher, Rochester, NY).  After 7-9 days, the cells were harvested with 0.25% trypsin-
EDTA (Invitrogen), counted and used experimentally.  Cells were not permitted to expand 
beyond 70% confluence and were frozen in αMEM supplemented with 30% serum and 5% 
DMSO.  For experimental use, all four MSC donor cells were quickly thawed to 37˚C and placed 
in four 10-mm Nuncleon culture plates with CCM to recover from freezing.  The next day the 
cells were removed from the plates with trypsin-EDTA and counted.  Equal quantities of each 
donor MSCs were combined and placed in Nuncleon culture plates at 50 cells per cm
2
.  After 7 
days, the cells were harvested with 0.25% trypsin-EDTA, counted and used experimentally.   
 
4.3 Osteogenic Differentiation:   
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AFS cells or MSCs were cultured at 20,000 cells per cm
2
 in 6 well plates (Nunc, 
Rochester, NY) in either modified Chang media (AFS cells) or CCM (MSCs), N = 6 for all 
conditions.  After allowing the cells to attach to the culture dish for 24 hours, the media was 
changed to the osteogenic induction conditions, which comprised CCM media supplemented 
with1 μM Dexamethasone, 6 mM β-glycerol phosphate, 50 μg/ml Ascorbic acid 2-Phosphate, 
and 50 ng/ml Thyroxine (all Sigma, St. Louis, MO)[10]. Control samples of both MSCs and AFS 
cells were grown in CCM to exclude spontaneous differentiation.  The media was changed 2 
times per week.  Cells were analyzed 2 and 4 weeks after the start of differentiation.   
 
4.4 Alizarin Red S Staining for Calcium: 
The cells were washed with excess PBS (Mg
2+
 and Ca
2+
 free, Invitrogen) and fixed in 
10% neutral buffered formalin (Sigma) for 15 minutes.  The cells were washed 3x with water, 
then stained with 2 ml 0.4mM Alizarin red S (pH 4.2, Sigma) for 20 minutes with rocking.  
Calcium forms an alizarin red S-calcium complex in a chelation process, producing a dark red 
stain. The excess Alizarin red S stain was removed and using vigorous washing with excess 
water (4 times for 5 minutes each, with rocking).  Stained monolayers were visualized by phase 
microscopy using an inverted microscope (Nikon, Melville, NY).   
 
4.5 Gene Expression by real-time RT-PCR: 
 For each cell type, 50,000 cells per cm
2
 were placed into 6 well dishes and cultured 
overnight in CCM.  After allowing the cells to attach to the culture dish for 24 hours, the media 
was changed to osteogenic media and the media was changed every 3 days throughout the 
culture.  Cells were harvested at days 0, 1, 2, 3, 5, 7, 10 and 14 using a cell scraper (Nunc) and 
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the RNA was isolated using Qiagen RNEasy Plus kit according to the manufacturer’s 
instructions.  cDNA was produced from 1 μg total RNA using Superscript III First-strand 
Synthesis SuperMix according to manufacturer’s instructions (Invitrogen).  Real-time PCR was 
performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) with Power Sybr 
Green PCR Master Mix (Applied Biosystems).  The cycle threshold was normalized to GapDH 
and compared to a relative standard curve for each primer set.  Primer sequences and 
concentrations are given in Supplimentary Table S1. 
 
4.6 Scaffold preparation: 
3-dimensional sheets of PCL lattice comprised of 300 μm struts spaced 500 μm apart in a 
0, 60, 120 degree repeating pattern with 85% porosity and a height of 9mm were produced 
through fused deposition modeling as previously described[14, 30] with a height of 9 mm.  
Cylinders of a 6 mm diameter were cut from the sheet with a dermal biopsy punch (Miltex, 
York, PA).  The cylinders were incubated in 5M NaOH for 2 hours at 37˚C to clean and partially 
degrade the scaffold surface, thereby increasing surface roughness.  The scaffolds were then 
washed 3x in excess sterile water and sterilized through 70% ethanol evaporation.   
To produce a collagen network throughout the pores of the PCL lattice, a collagen gel 
was produced with type 1 rat tail collagen (Vitrogen, Fremont, CA).  Briefly, 100 parts collagen 
(1.4 mg/ml in 0.05% acetic acid) was combined with 9 parts sodium bicarbonate, and 250 μl was 
placed in a custom mold.  The PCL cylinder was then placed in the mold/collagen and the 
collagen allowed to gel for 30 minutes at room temperature, and then cooled to -80˚C for 2 
hours.  The PCL/collagen was then placed in a lyophilizer overnight (Labconco, Kansas City, 
MO).  After lyophilization, the scaffolds were removed from the mold and placed in a 12 well 
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tissue culture dish (Nunc, low cell binding).  To maintain scaffold orientation during culture, the 
cylinders were placed in a holder consisting of a sterile 3/4” Teflon disk with 4 stainless steel 
pins surrounding the cylinder.   
 
4.7 Cell seeding onto PCL/collagen scaffolds: 
AFS cells and MSCs were expanded as described above.  Six million cells were 
resuspended in 150 μl of modified Chang media or CCM and slowly placed drop-wise on the top 
of the scaffold.  The media were readily absorbed by the collagen mesh, with minimal pooling at 
the bottom.  The cell/scaffold was placed in the 37˚C incubator for 1 hour to promote cell 
attachment, after which time 4 ml of modified Chang media or CCM was carefully added to each 
well. The scaffolds were cultured under static conditions for 3 days to allow the cells to attach to 
the scaffold.   
After 3 days, the media was carefully aspirated and osteogenic media was added to each 
osteogenic sample and control samples were cultured in CCM.  At this time, the scaffolds were 
placed on a rocker plate to increase media perfusion through the scaffold (Belly Button® orbital 
shaker, 7.5 rpm, minimal pitch, Stovall, Greensboro, NC).  The media was changed every 2-3 
days for 15 weeks.   
The seeding efficiency was determined at day 3, prior to the placement in osteogenic 
media.  The scaffolds were washed 2x with PBS to remove unattached cells.  The scaffolds were 
then immersed in 1ml of Trypsin-EDTA for 5 minutes at 37˚C.  The trypsin was inactivated with 
5ml complete culture media and the cells pelleted by centrifugation at 450xg for 10 minutes.  
The cell pellets were resuspended in 3 ml CCM, stained with trypan blue and counted in 
duplicate on a hemocytometer.  N=4. 
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4.8 MicroCT scan: 
At 3, 5, 10, and 15 weeks, the scaffolds were removed from the Teflon holders and 
placed in a sterile polysulfone sample holder.  Mineralization of the scaffolds was quantified 
using the VivaCT (Scanco Medical, Switzerland) at a 21.5 voxel resolution.   Samples were 
evaluated at a threshold of 80, a filter width of 1.2, and filter support of 1.  For each scaffold, a 
measurement of the volume filled with hydroxyapatite was determined.  The samples were then 
removed aseptically from the sample holder and returned to the Teflon holder for further culture.  
N=12. 
 
4.9 Calcium Assay: 
At 15 weeks in either osteogenic or control media, the scaffold was dissected into 4 
sections by slicing in a custom matrix so that each scaffold was cut vertically across the diameter 
of the cylinder and horizontally to produce 4 sections of equal size.  ¼ of the scaffold, ½ of the 
top half of each scaffold, was used to determine the calcium within the matrix.  Each scaffold 
was placed in 500μl of 1M acetic acid and placed on a vortex overnight at 4˚C to extract the 
calcium from the mineralized matrix.   
In a 96 well clear polycarbonate plate, 25μl of cell extract were mixed with 300μl of 
calcium reagent (arsenazo III, Diagnostic Chemicals Limited) and the absorbance determined at 
615-nm with a spectrophotometer.  N=6. 
 
4.10 DNA Assay: 
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The PicoGreen DNA quantification kit (Invitrogen) was used to following the protocol 
recommended by the manufacturer to determine at 15 weeks the relative amount of DNA within 
scaffolds from the different experimental groups.  Lambda DNA standards were produced from 
1µg to 1ng.  The cell lysates were diluted 1:10 in Tris-EDTA buffer.  100 µl of the PicoGreen 
working solution and 100µl of each sample were placed in triplicate, in black 96-well plates.  
After a 5-minute incubation, the fluorescence was determined at an excitation of 485-nm and an 
emission of 535-nm (Perkin-Elmer HTX 7000 fluorescent plate reader, Waltham, MA). N=6. 
 
4.11 Cell Viability Staining: 
Cell viability at 15 weeks was determined using the LIVE/DEAD Viability/Cytotoxicity 
Kit for mammalian cells according to manufacturer’s instructions (Molecular Probes, 
Invitrogen).  Briefly, scaffolds were cut longitudinally and washed 3 times in excess PBS and 
then incubated for 45 minutes in 4 μM Calcein AM and 4 μM Ethidium homodimer-1 with 
gentle shaking.  The scaffolds were then washed 3 times with PBS and analyzed using a confocal 
microscope (LSM 510 UV, Carl Zeiss, Thornwood, NY).  Micrographs were taken on the 
exterior surfaces:  top, bottom, and outside surfaces as well as the cut surface to check the 
viability at the core of the scaffold.  
 
4.12 Histology: 
For histological examination, scaffolds were removed from culture at 15 weeks and fixed 
in 4% paraformaldehyde. An ethanol gradient (30 minutes in 70%, 1 hour in 90%, 95% and 
100% ethanol) was used to dehydrate the samples. They were next processed three times through 
xylenes for 40 minutes each, infiltrated with methylmathacrylate (MMA) for 3h and embedded 
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in MMA containing 3% PEG softener. Five micrometre sections were cut with an 
osteomicrotome (SM2500; Leica Microsystems, Wetzlar, Germany), stretched flat with 70% 
ethanol onto a polylysine coated microscope slide (Lomb Scientific), overlayed with a plastic 
film and slides were clamped together before being dried overnight at 50°C. Sections were then 
stained using combined von Kossa and van Giesen stains to visualise the mineralised bone and 
connective tissue respectively [41].  
 
4.13 Data Analysis: 
 Data are reported as mean +/- SE and statistical analyses was performed using Graphpad 
Prism 5 software using a general linear model (ANOVA) and Tukey’s post-hoc analysis with 
Bonferroni adjustment or pair wise comparisons; with p< 0.05 considered significant. 
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8 Supplementary Table: 
Primer  Forward 
Conc 
(pM) 
Reverse 
Conc 
(pM) 
Osteocalcin GCAAAGGTGCAGCCTTTGTG 300 GGCTCCCAGCCATTGATACAG 900 
Alkaline 
Phosphatase 
CGTGGCTAAGAATGTCATCATGTT 900 TGGTGGAGCTGACCCTTGA 900 
Runx2 TGATGACACTGCCACCTCTG 300 GGGATGAAATGCTTGGGAAC 300 
GapDH ACCACAGTCCATGCCATCAC 300 TCCACCACCCTGTTGCTGTA 300 
 
Supplementary Table 1:  The sequence and concentration of the primers used for real-time 
PCR.   
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9 Figure Legends 
 
Figure 1: A.  To compare the amount of alizarin red staining of the mineralized matrix produced 
by the cells, the dye was extracted and the absorbance determined spectrophotometrically to 
determine the temporal changes in mineralized matrix.  At 2 and 4 weeks the AFS cells had 
produced significantly more mineralized matrix than the MSCs.  B. Calcium deposition by the 
AFS cells and MSCs was confirmed and quantified using the Arsenazo III reagent at 4 weeks.  
The AFS cells deposited significantly more calcium than the MSCs (p< 0.001).  Both the AFS 
cells and MSCs deposited significantly more calcium than their control counterpart (n=6, p< 
0.01).  Real-time PCR quantification of Runx2 (C), Alkaline Phosphatase (D) and Osteocalcin 
(E) illustrate the temporal fluctuation of mRNA typical of osteoblasts.  The MSCs had an early 
increase in transcript levels, which then decreased.  The AFS cells required a longer induction 
time before the mRNA levels were increased. (n= 3, P<0.05) 
 
Figure 2:  MSCs and AFS cells induced to produce mineralized matrix within the PCL scaffold.  
The scaffolds were aseptically scanned by microCT at weeks 3, 5, 10 and 15.  The mineral 
volume of the same scaffold is shown for the A1 AFS cells, H1 AFS cells, and MSCs to illustrate 
the change in mineralized matrix over time.  The mineralization of the PCL scaffold by the AFS 
cells is much more extensive, with the mineral distributed throughout the scaffold.  The mineral 
produced by the MSCs is primarily found on the interior of the scaffold.    N=12 
 
Figure 3:  A.  The volume of mineralized matrix produced by the osteogenic and control cells 
within the PCL scaffold was determined by microCT.  At all time points there was significantly 
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more mineral in the osteogenic scaffolds than the control scaffolds (p< 0.001).  At 3 and 5 
weeks, significantly more mineral was produced by the MSCs than the AFS cells (p< 0.001).  At 
10 and 15 weeks, both AFS cell lines produced significantly more mineral than the MSCs (p< 
0.001).  At 15 weeks, the H1 AFS line also produced significantly more mineral than the A1 cell 
line.  N=6 for controls, n=12 for osteogenic.  B.  The rate of mineral deposition was calculated 
for each scaffold and then compiled with its cohort.  The rate of mineral deposition was 
significantly higher in the osteogenic MSCs at 3 weeks (p< 0.001) when compared to osteogenic 
AFS cells, but at 5 weeks the rate of mineralization between the three osteogenic groups was not 
significantly different.  At 10 and 15 weeks, the rate of mineralization of the osteogenic AFS cell 
groups was significantly greater than the osteogenic MSCs.  At 15 weeks, the H1 mineralization 
rate was greater than the A1 AFS cell mineralization.  At 10 and 15 weeks, the rate of 
mineralization of the MSCs was not significantly different from the control groups. N=6 for 
controls, n=12 for osteogenic.  (p< 0.001).   N=6 for controls, n=12 for osteogenic.   
 
Figure 4:  A. The calcium produced by the cells during the 15 weeks in culture was compared 
and quantified using the Arsenazo III reagent.  25% of the scaffold was used for this comparison.  
The AFS cells produced significantly more mineralized matrix than the MSCs when cultured in 
osteogenic media (p<0.001).  Both cells produced significantly more mineralized matrix in 
osteogenic media than when cultured in control media (p<0.001 for AFS cells, p<0.01 for 
MSCs).  B.  Cell viability of the cells at 15 weeks in culture was determined by Calcien AM 
staining for live cells and ethidium homodimer-1 staining of the nuclei of dead cells. The exterior 
surfaces (top, bottom and outer surface) along with the middle of the scaffold (produced by 
cutting the scaffolds longitudinally) were visualized by confocal microscopy.  Few dead cells 
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were seen in the scaffolds and cells can be seen throughout the scaffolds, including spanning the 
pore space between the PCL struts.  C.  The cell attachment of the AFS cells and MSCs to the 
PCL scaffolds was determined by cell count after 3 days in culture.   No differences were seen 
between the two groups. N=6.  D.  The cell proliferation and survival was similar after the 15 
weeks in 3D culture, whether the scaffolds were seeded with MSCs or AFS cells and cultured in 
osteogenic or control media.  N=6.   
 
Figure 5:  Histology revealed the onset of ectopic bone formation for osteoinduced MSC and 
AFS cells when seeded into 3D PCL scaffolds and cultured for 15 weeks.  MSC control cell 
scaffold show no mineralisation, only fibrous tissue formation, which stained pink (A-D). Clear 
black mineral deposition can be observed for osteinduced MSCs (E-H) and AFS cells (I-P), 
within a fibrous network penetrating the scaffold pores. 
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10 Supplementary Figures: 
Supplementary Figure 1:  A-C.  Low density photomicrographs show the morphology of the 
AFS cells and the MSCs.  Both the AFS cells and MSCs show heterogeneity, but the AFS cells 
(A and B) have a distinct small-sized cell population not seen in MSC culture (C).  Osteogenic 
capability of the MSCs and AFS cells can be seen in D-F.  Alizarin red S staining shows dense 
calcium deposits covering the cell layers.   
 
Supplementary Figure 2:  The mineralized matrix production by the MSCs and AFS cells on 
3D constructs is highly reproducible.  Representative scaffolds of the osteogenic AFS cells and 
MSCs at 15 weeks are shown to illustrate the distribution of mineralized matrix through the PCL 
scaffold.   Scaffolds 1-4 (of 12) of each cell type are shown for comparison.   
 
Supplementary Figure 3:  The extracellular matrix accumulation can be easily visualized at 15 
weeks in vitro in all scaffolds seeded with MSCs or AFS cells in both control and osteogenic 
media.  The highly porous nature of the scaffold can be seen in the no cell control.    The arrow 
points to the white calcified area of the MSC scaffold which is also seen on the microCT images.  
Additionally, the osteogenic AFS cells produced a white calcified shell around the scaffold. 
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